Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Retained Earnings (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Retained Earnings for 4 consecutive years, with -$1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 17.52% to -$1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 billion, a 17.52% decrease, with the full-year FY2025 number at -$1.5 billion, down 17.52% from a year prior.
  • Retained Earnings was -$1.5 billion for Q4 2025 at Phathom Pharmaceuticals, down from -$1.5 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$570.0 million in Q1 2022 to a low of -$1.5 billion in Q4 2025.
  • A 4-year average of -$1.0 billion and a median of -$970.1 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 39.98% in 2024, then dropped 17.52% in 2025.
  • Phathom Pharmaceuticals' Retained Earnings stood at -$727.1 million in 2022, then dropped by 27.73% to -$928.7 million in 2023, then crashed by 36.0% to -$1.3 billion in 2024, then dropped by 17.52% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Retained Earnings are -$1.5 billion (Q4 2025), -$1.5 billion (Q3 2025), and -$1.4 billion (Q2 2025).